The UK and US have announced a significant commercial pact that will guarantee no tariffs on UK pharmaceutical shipments being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to raise expenditure on medicines through the NHS. This pledge guarantees that tariffs on these key exports will be held at zero for a timeframe of 36 months.
This agreement follows recent statements to dramatically increase tariffs on patented drug products, with figures mentioned up to 100%.
"This agreement between the Britain bolsters the worldwide climate for innovative medicines and introduces much-needed balance to transatlantic medicine commerce," a statement noted.
Economic Significance
Medicines constitute one of the the United Kingdom's largest exports to the United States, which is by far the biggest destination for large British pharmaceutical firms.
Trade data reveal that in the 12 months to the end of last September, the UK sold drugs worth billions to the US. This amount made up nearly one-fifth of British export trade in that timeframe.
"This deal secures work, increases investment and sets the stage for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The deal involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a target to double overall health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must return to the NHS to stay within budget will be restricted at 15%. Last year, repayments exceeded 20%.
Recent Tensions
The pact comes amid a protracted row between the drug companies and the UK government over medicine costs and NHS adoption.
These tensions were exacerbated by claims that US patients were paying a premium for the same drugs than consumers in the other developed nations.
In recent months, several major drug company projects in the UK have been paused or scrapped, while substantial investments have been announced toward US facilities.
A senior figure publicly accepted that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
